Studies of the dysglycemic peptide, pancreastatin, using a human forearm model.

Abstract

The physiologic effects of the chromogranin A peptide fragment, pancreastatin, were studied in six healthy Caucasian men, ages 25-46 years. Synthetic pancreastatin (human chromogranin A(273-301)-amide) was infused into the brachial artery of each subject to achieve a local concentration of approximately 200 nM over 15 minutes. Forearm blood flow was measured by strain-gauge plethysmography while (A-V)(glucose) was monitored by arterial and venous sampling. Pancreastatin infusion significantly reduced forearm glucose uptake (mean reduction +/- 1 SEM, 54 +/- 15%; P = 0.028) but did not alter forearm blood flow-indicating a metabolic, rather than hemodynamic, effect. Simultaneous infusion of pancreastatin with insulin (0.1 mU/kg/min) did not diminish insulin-induced forearm glucose uptake, suggesting pancreastatin is not simply a negative insulin modulator. The results of this study suggest that pancreastatin may contribute to the dysglycemia associated with type 2 diabetes and essential hypertension, two common human disease states in which plasma pancreastatin levels are elevated.

• Authors: Peter E Cadman, Fangwen Rao, Sushil K Mahata, Daniel T O'Connor
• Journal: Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 971 Pg. 528-9 (Oct 2002) ISSN: 0077-8923 [Print] United States
• PMID: 12438174 (Publication Type: Journal Article)

Chemical References

• Blood Glucose
• Chromogranin A
• Pancreatic Hormones
• pancreastatin
• Glucose

Topics

• Adult
• Arm (blood supply)
• Blood Flow Velocity (drug effects)
• Blood Glucose (metabolism)
• Chromogranin A
• Diabetes Mellitus, Type 2 (physiopathology)
• Glucose (pharmacokinetics)
• Hemodynamics
• Humans
• Male
• Middle Aged
• Muscle, Skeletal (drug effects, metabolism)
• Pancreatic Hormones (chemistry, physiology)